glp 1/gip Frontiers Why does GLP‐1 agonist combined
Description
sitagliptin OR: 2.7, p = 0.008) and thyroid cancer (exenatide OR: 4.73, p = 0.004) [161]
Low prices are expected to lead to more accessibility and higher demand
Journal of the American Chemical Society
Dulaglutide utilises a large recombinant fusion protein with Fc fragment for prolonged action, achieving a 5-day half-life with once-weekly dosing [29]
In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of 15.0%, 19.5%, and 20.9% at studied doses compared with 3.1% with placebo over 72 weeks
